CorMedix (NASDAQ:CRMD - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect CorMedix to post earnings of ($0.27) per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
CorMedix (NASDAQ:CRMD - Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). On average, analysts expect CorMedix to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CorMedix Price Performance
CRMD stock traded down $0.05 on Tuesday, hitting $5.84. 466,592 shares of the company were exchanged, compared to its average volume of 557,279. CorMedix has a twelve month low of $2.57 and a twelve month high of $7.00. The business's fifty day moving average is $4.53 and its two-hundred day moving average is $3.79. The stock has a market capitalization of $320.10 million, a price-to-earnings ratio of -6.35 and a beta of 1.79.
Wall Street Analyst Weigh In
Several equities analysts recently commented on CRMD shares. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of CorMedix in a research report on Tuesday, April 9th. Truist Financial dropped their price target on shares of CorMedix from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, January 31st. Royal Bank of Canada dropped their price objective on shares of CorMedix from $10.00 to $9.00 and set an "outperform" rating for the company in a research report on Wednesday, March 13th. Finally, JMP Securities reissued a "market outperform" rating and issued a $19.00 price objective on shares of CorMedix in a research report on Tuesday, April 9th.
View Our Latest Analysis on CRMD
Insider Transactions at CorMedix
In other CorMedix news, CEO Joseph Todisco acquired 13,561 shares of the company's stock in a transaction dated Wednesday, March 13th. The stock was bought at an average price of $3.74 per share, with a total value of $50,718.14. Following the completion of the transaction, the chief executive officer now directly owns 352,839 shares of the company's stock, valued at $1,319,617.86. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.60% of the company's stock.
About CorMedix
(
Get Free Report)
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Further Reading
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
